Nontuberculous Mycobacterial Infections at a National Cancer Institute–Designated Comprehensive Cancer Center in Florida
Open Forum Infectious Diseases · 01.08.2026 · 13 (8)
DOI: 10.1093/ofid/ofag467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 29.07.2026. Verfasst von Yanina Pasikhova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Moffitt Cancer Center, Tampa, Florida, USA. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Nontuberculous mycobacteria (NTM) are environmental organisms that become opportunistic pathogens in certain populations. NTM prevalence has increased globally, likely due to increased diagnostic testing and the availability of population-based studies. Current literature on oncology patients is minimal and represents a unique study area. Here we present the epidemiology and treatment of NTM infection cases at a National Cancer Institute–designated comprehensive cancer center.
Methods
We performed a retrospective single-center cohort study of adults with microbiologically proven NTM infections presenting from 2020 to 2023. Epidemiologic and treatment-related data were retrieved from the electronic medical record and evaluated to illustrate institutional patterns.
Results
A total of 93 patients met assessment criteria, with most (74 of 93 [80%]) having a past or active cancer. Mycobacterium avium complex (47 of 93 [51%]) and Mycobacterium abscessus group (28 of 93 [30%]) were the most common isolates. The majority were pulmonary infections (75 of 93 [81%]), with the integument accounting for most extrapulmonary sites (14 of 18 [78%]). Of 93 patients, 49 (53%]) received therapy, with many (41 of 49 [84%]) receiving ≥3 agents. Thirty-nine (80%]) required an initial regimen modification, and 13 (27%) received dual β-lactam therapy (frequently including meropenem). Of treated patients, 36 (73%) demonstrated improved symptoms, 18 (37%) improved or partially improved radiologic change, and 19 (39%]) sustained culture conversion to negative at the evaluation time point; 13 (27%) died or were lost to follow-up.
Conclusions
Our report offers one of the largest single-center epidemiologic perspectives on NTM infections in oncology patients. It offers unique insight into treatment practices in this population, particularly regarding dual β-lactam therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Moffitt Cancer Center, Tampa, Florida, USA.
- Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Internal Medicine, Moffitt Cancer Center, Tampa, Florida, USA.
- Division of Infectious Diseases and International Medicine, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
ORCID-Profile: Matthew Snyder, Austin Morrison, Guy Handley, Misbahuddin Syed, Anthony P Cannella
Zitieren
APA
Pasikhova, Y., Snyder, M., Morrison, A., Handley, G., Syed, M., & Cannella, A. P. (2026). Nontuberculous Mycobacterial Infections at a National Cancer Institute–Designated Comprehensive Cancer Center in Florida. Open Forum Infectious Diseases, 13(8). https://doi.org/10.1093/ofid/ofag467
Vancouver
Pasikhova Y, Snyder M, Morrison A, Handley G, Syed M, Cannella AP. Nontuberculous Mycobacterial Infections at a National Cancer Institute–Designated Comprehensive Cancer Center in Florida. Open Forum Infectious Diseases. 2026;13(8). doi:10.1093/ofid/ofag467
BibTeX
@article{Pasikhova2026,
author = {Pasikhova, Yanina and Snyder, Matthew and Morrison, Austin and Handley, Guy and Syed, Misbahuddin and Cannella, Anthony P},
title = {Nontuberculous Mycobacterial Infections at a National Cancer Institute–Designated Comprehensive Cancer Center in Florida},
journal = {Open Forum Infectious Diseases},
year = {2026},
volume = {13},
number = {8},
doi = {10.1093/ofid/ofag467}
}
EUVIMED